Cancer Across the Lifespan: Precision Strategies for Pediatric and Geriatric Oncology

Abstract

Cancer is a heterogeneous disease manifesting distinct molecular, clinical, and epidemiological profiles across the lifespan. Pediatric and geriatric oncology represent two ends of the age continuum, each with unique biological characteristics, therapeutic challenges, and survivorship considerations. This review synthesizes recent evidence and guideline-based strategies to optimize precision medicine in these populations, emphasizing individualized approaches to diagnosis, risk stratification, and management. We highlight the role of age-specific pathophysiological mechanisms, epidemiological trends, and the need for tailored therapeutic interventions, drawing on recent advances in molecular diagnostics, targeted therapies, and supportive care. The article aims to equip clinicians with clinically actionable insights for improving outcomes in pediatric and geriatric patients with cancer.

Introduction

Cancer remains a leading cause of morbidity and mortality worldwide, but its presentation and management differ significantly between children and older adults. While pediatric cancers are often embryonal or hematological in origin and driven by developmental pathways, geriatric malignancies are typically epithelial, associated with cumulative genetic mutations, comorbidities, and age-related physiological changes. Understanding these distinctions is critical for implementing precision oncology, ensuring that diagnostic, therapeutic, and supportive measures are tailored to the biological and clinical needs of each age group. This review explores current evidence and best-practice guidelines for pediatric and geriatric oncology, emphasizing precision strategies and emerging innovations that hold promise for improved patient outcomes.

Epidemiology / Disease Burden

Pediatric cancers account for approximately 1-2% of all malignancies, with an annual global incidence of 140-160 cases per million children. The most common types include acute lymphoblastic leukemia (ALL), brain tumors, and neuroblastoma. In contrast, over 60% of all cancers occur in adults aged 65 and above, reflecting the cumulative impact of aging and environmental exposures. The geriatric population faces a rising cancer burden due to increased life expectancy and demographic shifts. Disease trajectory, survival rates, and late effects differ substantially between these populations, underscoring the necessity for age-specific epidemiological surveillance and resource allocation.

Pathophysiology

Pediatric malignancies are frequently linked to genetic predispositions, germline mutations (e.g., TP53, RB1), and aberrant developmental signaling pathways. These tumors often demonstrate high proliferative rates but may have fewer somatic mutations than adult cancers. Conversely, geriatric cancers commonly result from accumulated DNA damage, epigenetic alterations, and immunosenescence. Age-associated changes in the tumor microenvironment, such as increased inflammation and altered stromal interactions, further influence tumor biology and therapeutic response. Understanding these mechanistic differences is essential for guiding diagnostic and therapeutic precision.

Risk Factors

In children, established risk factors include inherited cancer syndromes (e.g., Li-Fraumeni, familial retinoblastoma), prenatal exposures, and, less commonly, environmental carcinogens. In older adults, risk is influenced by lifestyle factors (tobacco, alcohol, diet), chronic inflammation, viral oncogenesis (e.g., HPV, EBV), and age-related decline in DNA repair mechanisms. Polypharmacy and comorbid conditions further complicate risk assessment and therapeutic decision-making in geriatric oncology. Precision assessment of risk factors enables early intervention and individualized prevention strategies.

Clinical Features

Pediatric cancers often present with rapidly progressive symptoms such as unexplained fever, pallor, bruising, or palpable masses. Delays in diagnosis can occur due to nonspecific presentations or low suspicion in primary care settings. In contrast, geriatric patients may exhibit atypical or insidious symptoms, compounded by cognitive impairment or masking by comorbid illnesses. Comprehensive geriatric assessment is recommended to evaluate functional status, frailty, and psychosocial factors that influence clinical presentation and management.

Diagnosis

The diagnostic approach in pediatrics emphasizes minimally invasive methods, molecular profiling, and multidisciplinary evaluation. Techniques such as next-generation sequencing (NGS), cytogenetics, and liquid biopsies are increasingly utilized to refine classification and risk stratification. In older adults, diagnosis may be complicated by frailty, organ dysfunction, or polypharmacy, necessitating judicious use of imaging and biopsy. Biomarker-driven diagnostics and geriatric assessment tools are integral to precision oncology across the lifespan.

Treatment & Management

Pediatric oncology employs risk-adapted, protocol-driven regimens that balance efficacy with long-term toxicity reduction. Modalities include chemotherapy, targeted agents, immunotherapy, and, selectively, surgery or radiation. Geriatric oncology requires individualized treatment planning, accounting for physiologic reserve, comorbidities, polypharmacy, and patient preferences. Dose modifications, supportive care, and palliative interventions are critical components. Multidisciplinary care teams optimize therapeutic outcomes by integrating oncology, geriatrics, pharmacy, and psychosocial support.

Recent Advances / Emerging Therapies

Emerging therapies in pediatric oncology include CAR-T cell therapy for refractory leukemias, novel kinase inhibitors, and molecularly targeted agents informed by precision diagnostics. Advances in genomics have facilitated risk stratification and the development of less toxic regimens. In geriatrics, immunotherapy (e.g., checkpoint inhibitors) and oral targeted agents have expanded treatment options, though careful patient selection is required to avoid excess toxicity. Personalized medicine approaches, including pharmacogenomics and real-world data analytics, are reshaping therapeutic paradigms across age groups.

Guideline Recommendations

Current guidelines from ASCO, NCCN, and SIOP endorse multidisciplinary, risk-adapted care for both pediatric and geriatric oncology populations. In children, adherence to protocol-based therapy within clinical trials is emphasized. For older adults, comprehensive geriatric assessment, regular medication review, and shared decision-making are recommended to optimize outcomes. Integration of molecular diagnostics and psychosocial support is increasingly recognized as standard of care in both populations.

Conclusion

Precision oncology across the lifespan mandates a nuanced understanding of age-specific cancer biology, risk factors, and therapeutic challenges. Advances in molecular diagnostics, targeted therapies, and supportive care offer new opportunities for individualized management in pediatric and geriatric populations. Ongoing research, multidisciplinary collaboration, and patient-centered care are essential for realizing the full promise of precision medicine and improving cancer outcomes from childhood through advanced age.